source
- Helus Pharma’s Phase 3 trial shows strong depression benefit but safety concerns emergeHelus Pharma reported that its deuterated psilocin candidate HLP003 achieved the primary endpoint in a Phase 3 trial for major depressive disorder when added to patients' existing antidepressants.…
- FDA rejects ivonescimab for lung cancer; J&J to acquire Ollin Biosciences for up to $3.3B, Senate votes on FDA commissionerThe FDA has denied the application for ivonescimab as a treatment for lung cancer, halting its development for that indication. Johnson & Johnson announced a deal to purchase Ollin Biosciences, a…